Synthetic lipid-like molecules (lipidoids) are superior for intracellular delivery of various bioactive cargos. Through incorporating stimuli-responsive linkers, lipidoid nanoparticle-based delivery systems with triggered-release features can be constructed. Enhanced delivery performances have been achieved using disulfide bond-containing bioreducible lipidoids. Herein, we further expand the stimuli-responsive combinatorial lipidoids library by integrating the photocleavable -nitrobenzyl moiety into the hydrophobic tail of the lipidoids. The structures of these novel lipidoids were confirmed by NMR and MS. The nanoparticles were fabricated through self-assembly procedures, and their photoresponsive behaviors were examined. Light-regulated cargo release and following functionality restoration indicated the potential of the newly developed lipidoid nanoparticles for spatiotemporal delivery.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/acsbiomaterials.9b00445 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Messenger RNA (mRNA)-based therapies are a promising approach to medical treatment. Except for infectious diseases, no other disease has mRNA-based therapies available. The eye is an ideal model for mRNA therapeutic development because it requires limited dosing.
View Article and Find Full Text PDFCombinatorial design of siloxane-incorporated lipid nanoparticles augments intracellular processing for tissue-specific mRNA therapeutic delivery.
Nat Nanotechnol
October 2024
Department of Bioengineering, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Systemic delivery of messenger RNA (mRNA) for tissue-specific targeting using lipid nanoparticles (LNPs) holds great therapeutic potential. Nevertheless, how the structural characteristics of ionizable lipids (lipidoids) impact their capability to target cells and organs remains unclear. Here we engineered a class of siloxane-based ionizable lipids with varying structures and formulated siloxane-incorporated LNPs (SiLNPs) to control in vivo mRNA delivery to the liver, lung and spleen in mice.
View Article and Find Full Text PDFLow-Dose Mildronate-Derived Lipidoids for Efficient mRNA Vaccine Delivery with Minimal Inflammation Side Effects.
ACS Nano
August 2024
Zhejiang Key Laboratory of Smart Biomaterials, College of Chemical and Biological Engineering, Zhejiang University, Hangzhou, Zhejiang 310058, P. R. China.
mRNA vaccines have been revolutionizing disease prevention and treatment. However, their further application is hindered by inflammatory side effects, primarily caused by delivery systems such as lipid nanoparticles (LNPs). In response to this issue, we prepared cationic lipids (mLPs) derived from mildronate, a small-molecule drug, and subsequently developed the LNP (mLNP-69) comprising a low dose of mLP.
View Article and Find Full Text PDFMucosal IFNλ1 mRNA-based immunomodulation effectively reduces SARS-CoV-2 induced mortality in mice.
EMBO Rep
September 2024
ETHRIS GmbH, Planegg, Germany.
RNA vaccines elicit protective immunity against SARS-CoV-2, but the use of mRNA as an antiviral immunotherapeutic is unexplored. Here, we investigate the activity of lipidoid nanoparticle (LNP)-formulated mRNA encoding human IFNλ1 (ETH47), which is a critical driver of innate immunity at mucosal surfaces protecting from viral infections. IFNλ1 mRNA administration promotes dose-dependent protein translation, induction of interferon-stimulated genes without relevant signs of unspecific immune stimulation, and dose-dependent inhibition of SARS-CoV-2 replication in vitro.
View Article and Find Full Text PDFSystemic Administration of Neurotransmitter-Derived Lipidoids-PROTACs-DNA Nanocomplex Promotes Tau Clearance and Cognitive Recovery for Alzheimer's Disease Therapy.
Adv Healthc Mater
December 2024
Department of Neurology, Second Affiliated Hospital (Shanghai Changzheng Hospital) of Naval Medical University, Shanghai, 200003, China.
Alzheimer's disease (AD) poses a significant burden on the economy and healthcare systems worldwide. Although the pathophysiology of AD remains debatable, its progression is strongly correlated with the accumulation of tau aggregates. Therefore, tau clearance from brain lesions can be a promising strategy for AD therapy.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!